FIDUCIARY TRUST CO - APELLIS PHARMACEUTICALS INC ownership

APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 149 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.

Quarter-by-quarter ownership
FIDUCIARY TRUST CO ownership history of APELLIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$10,088,475
-59.6%
265,207
-3.2%
0.18%
-58.2%
Q2 2023$24,953,748
-30.2%
273,916
-49.5%
0.44%
-33.6%
Q1 2023$35,769,514
+25.3%
542,291
-1.8%
0.66%
+19.2%
Q4 2022$28,553,797
-25.5%
552,191
-1.6%
0.56%
-32.9%
Q3 2022$38,315,000
+50.0%
560,991
-0.7%
0.83%
+54.1%
Q2 2022$25,542,000
-11.0%
564,8260.0%0.54%
+4.5%
Q1 2022$28,699,000
+7.5%
564,826
-0.0%
0.52%
+17.3%
Q4 2021$26,706,000
+43.4%
564,841
-0.0%
0.44%
+32.6%
Q3 2021$18,619,000
-47.8%
564,876
+0.2%
0.33%
-52.0%
Q2 2021$35,642,000
+46.9%
563,950
-0.3%
0.69%
+40.2%
Q1 2021$24,263,000
-26.0%
565,450
-1.3%
0.49%
-28.0%
Q4 2020$32,779,000
+90.4%
573,071
+0.4%
0.68%
+68.2%
Q3 2020$17,215,000
-11.1%
570,591
-3.7%
0.41%
-15.2%
Q2 2020$19,354,000
+22.1%
592,591
+0.1%
0.48%
+4.1%
Q1 2020$15,852,000
-12.0%
591,712
+0.5%
0.46%
+9.5%
Q4 2019$18,021,000
+6.0%
588,538
-16.6%
0.42%
-1.6%
Q3 2019$17,005,000
-4.7%
705,923
+0.2%
0.43%
-8.8%
Q2 2019$17,845,000
+29.7%
704,248
-0.2%
0.47%
+26.5%
Q1 2019$13,758,000
+47.8%
705,5480.0%0.37%
+29.8%
Q4 2018$9,306,000705,5480.28%
Other shareholders
APELLIS PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
AJU IB Investment Co., Ltd. 1,114,962$63,776,00024.13%
Octagon Capital Advisors LP 548,374$31,367,00010.87%
Ghost Tree Capital, LLC 325,000$18,590,0004.14%
Burrage Capital Management LLC 81,357$4,654,0003.55%
Aufman Associates Inc 53,642$3,068,0002.75%
ACUTA CAPITAL PARTNERS, LLC 167,054$9,555,0002.60%
Cormorant Asset Management, LP 1,866,108$106,741,0002.54%
Tri Locum Partners LP 121,409$6,945,0002.52%
venBio Partners LLC 490,471$28,055,0002.48%
HHLR ADVISORS, LTD. 5,028,289$287,618,0002.29%
View complete list of APELLIS PHARMACEUTICALS INC shareholders